Afimoxifene

Afimoxifene is a selective estrogen receptor modulator whose active ingredient is 4-hydroxytamoxifen which is identical to the active metabolite of tamoxifen. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.